Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - 16 April 2019 (2)

Overview

The Therapeutic Goods Act 1989 was enacted to provide a regulatory framework for the approval, regulation, and monitoring of therapeutic goods in Australia. The Act was introduced to address the need for a comprehensive system to ensure that therapeutic goods available in Australia are of an acceptable quality, safety, and efficacy. Enacted by the Parliament of Australia, the Act aims to protect public health by regulating the importation, supply, manufacture, and advertising of therapeutic goods. The policy objective behind the Act is to ensure that therapeutic goods meet certain standards to safeguard the health and well-being of the Australian population. The publication of the list of manufacturers granted a licence to manufacture therapeutic goods is one way in which the Therapeutic Goods Administration implements this policy by maintaining oversight and ensuring compliance with the Act's requirements.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, and advertising of therapeutic goods within Australia. This Act encompasses a wide range of products, including medicines, medical devices, blood and blood components, and therapeutic appliances, ensuring they meet safety, quality, and efficacy standards. The Act applies to manufacturers, importers, sponsors, and suppliers of these goods, including businesses and institutions like the ones mentioned in the gazette, which are granted specific licences to operate within the framework of the Act. The geographic reach of the Act is national, with the Therapeutic Goods Administration (TGA) being the regulatory body responsible for its enforcement across the Commonwealth of Australia. Exclusions or exemptions from the Act are generally limited and often pertain to specific categories of goods or circumstances, as further detailed in the Act and its subordinate instruments. The application of the Act can be extended or restricted through regulations and guidelines issued under the authority of the Act, providing flexibility and specificity in its enforcement.

Key Provisions

The Therapeutic Goods Act 1989, in its section 38, provides the authority for the Secretary to grant licences to entities that wish to manufacture therapeutic goods. This legislation mandates that any entity wishing to manufacture therapeutic goods must obtain a licence from the Therapeutic Goods Administration (TGA). Section 38 specifically empowers the Secretary to issue these licences to eligible entities, thereby ensuring that only those who meet certain standards and criteria can manufacture these goods. The published list of licence holders, such as Australian Natural Industry Pty Ltd, Roche Products Pty Ltd, and Royal Hobart Hospital/Pharmacy Department, illustrates the entities that have been granted such licences. This transparency ensures that the public and other stakeholders are aware of who is authorised to manufacture therapeutic goods. The Act imposes various obligations on the entities granted licences to manufacture therapeutic goods. Firstly, these entities must adhere to stringent quality and safety standards as stipulated by the TGA. This includes maintaining proper manufacturing practices, ensuring that all therapeutic goods are produced in a manner that does not compromise their safety or efficacy. Additionally, the entities must comply with all relevant regulations and guidelines issued by the TGA. They are required to conduct regular audits and self-inspections to ensure ongoing compliance with these standards. Furthermore, the licence holders must submit detailed reports to the TGA on a regular basis, providing information on their manufacturing processes, quality control measures, and any incidents or issues that arise. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in serious consequences for the entities involved. The Act delineates various offences related to the unauthorised manufacture of therapeutic goods, the production of goods that do not meet safety standards, and the provision of misleading information to the TGA. In the event of a breach, the TGA has the authority to take action, including the suspension or revocation of the manufacturing licence. For more serious violations, entities may face fines, with the maximum penalties varying depending on the severity of the offence. In some cases, criminal charges may be pursued, leading to potential imprisonment for individuals involved in the breach. These stringent measures are in place to ensure that the highest standards of safety and quality are maintained in the manufacture of therapeutic goods.